Publication:
Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus

dc.contributor.authorCasado-Fernández, Guiomar
dc.contributor.authorCantón, Juan
dc.contributor.authorNasarre, Laura
dc.contributor.authorRamos-Martín, Fernando
dc.contributor.authorManzanares, Mario
dc.contributor.authorSánchez-Menéndez, Clara
dc.contributor.authorFuertes, Daniel
dc.contributor.authorMateos, Elena
dc.contributor.authorMurciano-Antón, María Aranzazu
dc.contributor.authorPerez-Olmeda, Mayte
dc.contributor.authorCervero, Miguel
dc.contributor.authorTorres, Montserrat
dc.contributor.authorRodríguez-Rosado, Rafael
dc.contributor.authorCoiras, Mayte
dc.contributor.funderAlfonso X el Sabio University (España)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderComunidad de Madrid (España)
dc.contributor.funderFundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
dc.date.accessioned2024-06-20T14:01:09Z
dc.date.available2024-06-20T14:01:09Z
dc.date.issued2024
dc.description.abstractIntroduction: HIV-1 infection may produce a detrimental effect on the immune response. Early start of antiretroviral therapy (ART) is recommended to preserve the integrity of the immune system. In fact, people with HIV (PWH) and normal CD4/CD8 ratio appear not to be more susceptible to severe forms of COVID-19 than the general population and they usually present a good seroconversion rate in response to vaccination against SARS-CoV-2. However, few studies have fully characterized the development of cytotoxic immune populations in response to COVID-19 vaccination in these individuals. Methods: In this study, we recruited PWH with median time of HIV-1 infection of 6 years, median CD4/CD8 ratio of 1.0, good adherence to ART, persistently undetectable viral load, and negative serology against SARS-CoV-2, who then received the complete vaccination schedule against COVID-19. Blood samples were taken before vaccination against COVID-19 and one month after receiving the complete vaccination schedule. Results: PWH produced high levels of IgG against SARS-CoV-2 in response to vaccination that were comparable to healthy donors, with a significantly higher neutralization capacity. Interestingly, the cytotoxic activity of PBMCs from PWH against SARS-CoV-2-infected cells was higher than healthy donors before receiving the vaccination schedule, pointing out the pre-existence of activated cell populations with likely unspecific antiviral activity. The characterization of these cytotoxic cell populations revealed high levels of Tgd cells with degranulation capacity against SARS-CoV-2-infected cells. In response to vaccination, the degranulation capacity of CD8+ T cells also increased in PWH but not in healthy donors. Discussion: The full vaccination schedule against COVID-19 did not modify the ability to respond against HIV-1-infected cells in PWH and these individuals did not show more susceptibility to breakthrough infection with SARS-CoV-2 than healthy donors after 12 months of follow-up. These results revealed the development of protective cell populations with broad-spectrum antiviral activity in PWH with normal CD4/CD8 ratio and confirmed the importance of early ART and treatment adherence to avoid immune dysfunctions.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThe author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grant 1.013.022 funded by Universidad Alfonso X El sabio (Madrid, Spain); grant PI22CIII/00059 funded by the Strategic Action in Health of the Instituto de Salud Carlos III (ISCIII) and CIBERINFEC, co-financed by the European Regional Development Fund (ERDF) “A way to make Europe”; and by grants PID2019-110275RB-I00 and PID2022-141317OB-I00 funded by the Spanish Ministry of Science and Innovation, MICIU/AEI/10.13039/501100011033, ERDF, and EU. The work of GC-F is funded by the Consejerı́a de Educación, Universidades, Ciencia y Portavocı́a of the Comunidad de Madrid (Spain). The work of FRM is financed by the Spanish Ministry of Science and Innovation (PID2019-110275RB-I00). The work of MMa is supported by a predoctoral grant from Instituto de Salud Carlos III (ISCIII-PFIS FI20CIII/00021). The work of CS-M is financed by Programa Investigo, FIBio HRC-IRYCIS, co-financed by FEDER. The work of MT is financed by CIBERINFEC (CB21/13/00015).es_ES
dc.format.page1362621es_ES
dc.format.volume15es_ES
dc.identifier.citationFront Immunol. 2024 May 15:15:1362621.es_ES
dc.identifier.doi10.3389/fimmu.2024.1362621es_ES
dc.identifier.e-issn1664-3224es_ES
dc.identifier.journalFrontiers in immunologyes_ES
dc.identifier.pubmedID38812512es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19813
dc.language.isoenges_ES
dc.publisherFrontiers Media
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-110275RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2022-141317OB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-110275RB-I00es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III///PI22-ISCIII Proyectos de I+D+I en salud (AES 2022).Intramurales (2022)/PI22CIII/00059es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/FI20CIII/00021es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00015es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2024.1362621es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPeople with HIVes_ES
dc.subjectCOVID-19 vaccinationes_ES
dc.subjectTgd cellses_ES
dc.subjectCellular immune responsees_ES
dc.subjectHumoral immune responsees_ES
dc.subject.meshSARS-CoV-2es_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshHIV Infectionses_ES
dc.subject.meshCD4-CD8 Ratioes_ES
dc.subject.meshHumanses_ES
dc.subject.meshMalees_ES
dc.subject.meshFemalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshAdultes_ES
dc.subject.meshCOVID-19 Vaccineses_ES
dc.subject.meshCD8-Positive T-Lymphocyteses_ES
dc.subject.meshAntibodies, Virales_ES
dc.subject.meshHIV-1es_ES
dc.subject.meshCytotoxicity, Immunologices_ES
dc.subject.meshImmunoglobulin Ges_ES
dc.subject.meshT-Lymphocytes, Cytotoxices_ES
dc.subject.meshVaccinationes_ES
dc.titlePre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the viruses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationdda259fe-5ac5-4b19-9249-14c375ec516b
relation.isAuthorOfPublication5788952b-921a-48da-a0f1-565e8610b2e8
relation.isAuthorOfPublication5c0baf68-bb26-4041-a3c0-c7580e8f1d75
relation.isAuthorOfPublication7d3813df-5a95-4ec9-9511-fec2c9e10e8b
relation.isAuthorOfPublication70d4b634-f13f-4b35-a47e-5a337f5acbfc
relation.isAuthorOfPublicationd01866d4-34ba-4cd6-b995-3c4199bf0c59
relation.isAuthorOfPublicationf044fea9-eb43-475b-8602-1339d49f31f4
relation.isAuthorOfPublicationf729e106-ee5d-450a-b046-63b14e24c1a3
relation.isAuthorOfPublication.latestForDiscoverydda259fe-5ac5-4b19-9249-14c375ec516b
relation.isFunderOfPublication77ef4a4c-c3b2-425d-a72e-f66abb1888ff
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublicationc87c70a3-e023-4b6b-ac25-1b2d1b483786
relation.isFunderOfPublication5f48b5da-242b-496b-940d-aa9884414972
relation.isFunderOfPublication.latestForDiscovery77ef4a4c-c3b2-425d-a72e-f66abb1888ff
relation.isPublisherOfPublication9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery9f9fa5ea-093b-43d8-bf2c-5bd65d08a802

Files

Original bundle

Now showing 1 - 5 of 11
Loading...
Thumbnail Image
Name:
Pre-existingCellPopulationsCytotoxic_2024.pdf
Size:
1.88 MB
Format:
Adobe Portable Document Format
Description:
Articulo
Loading...
Thumbnail Image
Name:
Supplementary_table1_Pre-existingCellPopulations_2024.pdf
Size:
136.09 KB
Format:
Adobe Portable Document Format
Description:
supplementary material - Table 1
Loading...
Thumbnail Image
Name:
Supplementary_table2_Pre-existingCellPopulations_2024.pdf
Size:
277.83 KB
Format:
Adobe Portable Document Format
Description:
supplementary material - Table 2
Loading...
Thumbnail Image
Name:
Supplementary_figure1_Pre-existingCellPopulationsCytotoxic_2024.pptx
Size:
630.69 KB
Format:
Microsoft Powerpoint XML
Description:
Supplementary material - figure 1
Loading...
Thumbnail Image
Name:
Supplementary_figure2_Pre-existingCellPopulationsCytotoxic_2024.pptx
Size:
53.78 KB
Format:
Microsoft Powerpoint XML
Description:
Supplementary material - figure 2